CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-31 | Bennett Jean Director | Grant or award · Stock Options (Right to Buy) | +24,454 | 24,454 | ||
| 2024-05-31 | Fox Allan M. Director | Grant or award | +4,790 | 11,286 | ||
| 2024-05-31 | Fox Allan M. Director | Grant or award · Stock Options (Right to Buy) | +24,454 | 24,454 | ||
| 2024-05-31 | Tasse Daniel Director | Grant or award | +4,790 | 11,286 | ||
| 2024-05-31 | Tasse Daniel Director | Grant or award · Stock Options (Right to Buy) | +24,454 | 24,454 | ||
| 2024-05-31 | STUMP DAVID C Director | Grant or award | +4,790 | 11,286 | ||
| 2024-05-31 | STUMP DAVID C Director | Grant or award · Stock Options (Right to Buy) | +24,454 | 24,454 | ||
| 2024-05-14 | Mills Kenneth T. President and CEO | Option exercise 10b5-1 | +15,000 | $3.76 | $56K | 423,035 |
| 2024-05-14 | Mills Kenneth T. President and CEO | Sale 10b5-1 | −15,000 | $15.81 | $237K | 408,035 |
| 2024-05-14 | Mills Kenneth T. President and CEO | Option exercise · Stock Options (Right to Buy) 10b5-1 | −15,000 | 81,354 | ||
| 2024-04-15 | Mills Kenneth T. President and CEO | Option exercise 10b5-1 | +15,000 | $3.76 | $56K | 423,035 |
| 2024-04-15 | Mills Kenneth T. President and CEO | Sale 10b5-1 | −15,000 | $18.19 | $273K | 408,035 |
| 2024-04-15 | Mills Kenneth T. President and CEO | Option exercise · Stock Options (Right to Buy) 10b5-1 | −15,000 | 96,354 | ||
| 2024-03-19 | Vasista Vittal Chief Financial Officer | Option exercise | +20,041 | $3.76 | $75K | 246,534 |
| 2024-03-19 | Vasista Vittal Chief Financial Officer | Option exercise · Employee Stock Option (Right to Buy) | −20,041 | 0 | ||
| 2024-03-14 | Mills Kenneth T. President and CEO | Option exercise 10b5-1 | +15,000 | $3.76 | $56K | 423,035 |
| 2024-03-14 | Mills Kenneth T. President and CEO | Sale 10b5-1 | −15,000 | $21.86 | $328K | 408,035 |
| 2024-03-14 | Mills Kenneth T. President and CEO | Option exercise · Stock Options (Right to Buy) 10b5-1 | −15,000 | 111,354 | ||
| 2024-03-05 | PAKOLA STEVE Chief Medical Officer | Option exercise 10b5-1 | +12,878 | $22.25 | $287K | 120,070 |
| 2024-03-05 | PAKOLA STEVE Chief Medical Officer | Sale 10b5-1 | −12,878 | $28.36 | $365K | 107,192 |
Page 9 of 11 · 216 trades